AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$QTTB

Q32 Bio Inc.

Price · $QTTBvia TradingView
AI sentiment · 7d2 articles
MAY 22net (bullish − bearish)MAY 28
Bullish
2
Neutral
0
Bearish
0
Insider · 30dFeed →

No SEC Form 4 filings for $QTTB in the last 30 days.

Top stories · $QTTBMore →
MAY 28·rttnews.comMed

Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

MAY 27·rttnews.com

Q32 Bio Raises $55 Million In Private Placement; Stock Up

Q32 Bio Inc. (QTTB) said it will raise about $55 million in gross proceeds via a private placement. The company plans to sell 6.725 million common shares at $8.00 each plus 150,000 pre-funded warrants at $7.9999. Closing is expected May 28, 2026. BVF Partners leads, with RA Capital, OrbiMed and Atlas Venture participating; Morgan Stanley and Oppenheimer are placement agents.

MAR 21·Stock Titan

Q32 Bio (QTTB) awards 53,250 RSUs to its CFO and President

Q32 Bio Inc. (QTTB) reported that its CFO and President, Lee Kalowski, was granted 53,250 restricted stock units (RSUs) as part of his compensation. This award, valued at $0.00 per share, is not an open-market purchase. The RSUs will vest in four equal installments, beginning six months after the February 24, 2026 grant date, and subsequently at 12, 24, and 36 months, increasing Kalowski's direct holdings to 89,193 shares.

News on $QTTB